INS and Alzheimer disease: A clinical trial aimed at elucidating the effect of Insulin Sensitizer Metformin on AD Biomarkers (NCT01965756) used the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) to assess the potential of Metformin in mitigating AD-associated cognitive decline.